AACR 2021 was a virtual event including multiple Plenary Sessions and Major Symposia that delved on the most recent cancer research advances across a broad range of topics, including biological mechanisms, therapeutic approaches, and diagnostics. As part of the Exhibitor's presentations at the AACR Spotlight Theater, GenScript was honored to host two scientific talks highlighting the advantages of CRISPR and Monoclonal Antibody Services.
Characterization of a PARP inhibitor biomarker for cancer therapy
Speaker: Joshua Burgess, Ph.D. , Advance Queensland Early Career Research Fellow at QUT (Queensland University of Technology).
Abstract
A new generation of drugs has been developed that target the DNA repair enzyme PARP to induce DNA damage and cell death. PARP inhibitor therapy works on the fundamentals of synthetic lethality, where cells with defective homologous recombination repair, as seen in many cancers, are unable to repair PARP inhibitor-induced lesions induced. Our data demonstrate a new protein that functions in the repair of DNA damage, could be used as a companion diagnostic for PARP inhibitors. Our priority is to identify the cancer patients most likely to benefit from PARP inhibitor therapy, thereby personalizing patient care and improving survival.
Precise and Efficient Non-viral CRISPR Gene Editing Solutions
Speaker: Lumeng Ye, PhD., Sr. Scientist, GenScript USA Inc.
Abstract
With the 4th approval on CAR-T therapy (Breyanzi) by FDA in early 2021, ex vivo engineered T cell therapy was proved as a mainstay in cancer treatment. The delivery of specifically designed CAR or T CR encoding components can be done by viral vectors, but with limitations like random insertions and complicated manufacturing processes. With the power of CRISPR, precise and efficient T cell engineering can be carried out in a non-viral, plasmid-free manner. At this talk, we will show how GenScript can efficiently manufacture sgRNA and DNA payloads for precise CAR/TCR KI in T cells. With this upgraded capability and recent advances in non-viral delivery, efficiently and precisely engineer T cells with minimal off-targets is becoming a reality."
